Advanced

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma

Lalloo, UG; Malolepszy, J; Kozma, D; Krofta, K; Ankerst, Jaro LU ; Johansen, B and Thomson, NC (2003) In Chest 123(5). p.1480-1487
Abstract
Background: We evaluated the efficacy and safety of low-dose budesonide/formoterol, 80 mug/4.5 mug, bid in a single inhaler (Symbicort Turbuhaler; AstraZeneca; Lund, Sweden) compared with an increased dose of budesonide, 200 mug bid, in adult patients with mild-to-moderate asthma not fully controlled on low doses of inhaled corticosteroid alone. Methods: All patients received budesonide, 100 jig bid, during a 2-week run-in period. At the end of the run-in phase, 467 patients with a mean FEV1 of 82% predicted received 12 weeks of treatment with budesonide/formoterol in a single inhaler or budesonide alone in a higher dose. Patients kept daily records of their morning and evening peak expiratory flow (PEF), nighttime and daytime symptom... (More)
Background: We evaluated the efficacy and safety of low-dose budesonide/formoterol, 80 mug/4.5 mug, bid in a single inhaler (Symbicort Turbuhaler; AstraZeneca; Lund, Sweden) compared with an increased dose of budesonide, 200 mug bid, in adult patients with mild-to-moderate asthma not fully controlled on low doses of inhaled corticosteroid alone. Methods: All patients received budesonide, 100 jig bid, during a 2-week run-in period. At the end of the run-in phase, 467 patients with a mean FEV1 of 82% predicted received 12 weeks of treatment with budesonide/formoterol in a single inhaler or budesonide alone in a higher dose. Patients kept daily records of their morning and evening peak expiratory flow (PEF), nighttime and daytime symptom scores, and use of reliever medication. Results: The increase in mean morning PEF-the primary efficacy measure-was significantly higher for budesonide/formoterol compared with budesonide alone (16.5 L/min vs 7.3 L/min, p = 0.002). Similarly, evening PEF was significantly greater in the budesonide/formoterol group (p < 0.001). In addition, the percentage of symptom-free days and asthma-control days (p = 0.007 and p = 0.002, respectively) were significantly improved in the budesonide/formoterol group. Budesonide/formoterol decreased the relative risk of an asthma exacerbation by 26% (p = 0.02) compared with budesonide alone. Adverse events were comparable between the two treatment groups. Conclusion: This study shows that in adult patients whose mild-to-moderate asthma is not fully controlled on low doses of inhaled corticosteroids, single-inhaler therapy with budesonide and formoterol provides greater improvements in asthma control than increasing the maintenance dose of inhaled corticosteroid. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
formoterol, inhaled corticosteroids, long-acting, beta(2)-agonists, Symbicort, asthma, budesonide
in
Chest
volume
123
issue
5
pages
1480 - 1487
publisher
American College of Chest Physicians
external identifiers
  • pmid:12740264
  • wos:000182773000028
  • scopus:0038216589
ISSN
1931-3543
language
English
LU publication?
yes
id
a345bead-f5e5-4dfa-80ae-0531aac9d14a (old id 312178)
alternative location
http://www.chestjournal.org/cgi/content/abstract/123/5/1480
date added to LUP
2007-09-16 11:18:06
date last changed
2018-02-18 04:25:56
@article{a345bead-f5e5-4dfa-80ae-0531aac9d14a,
  abstract     = {Background: We evaluated the efficacy and safety of low-dose budesonide/formoterol, 80 mug/4.5 mug, bid in a single inhaler (Symbicort Turbuhaler; AstraZeneca; Lund, Sweden) compared with an increased dose of budesonide, 200 mug bid, in adult patients with mild-to-moderate asthma not fully controlled on low doses of inhaled corticosteroid alone. Methods: All patients received budesonide, 100 jig bid, during a 2-week run-in period. At the end of the run-in phase, 467 patients with a mean FEV1 of 82% predicted received 12 weeks of treatment with budesonide/formoterol in a single inhaler or budesonide alone in a higher dose. Patients kept daily records of their morning and evening peak expiratory flow (PEF), nighttime and daytime symptom scores, and use of reliever medication. Results: The increase in mean morning PEF-the primary efficacy measure-was significantly higher for budesonide/formoterol compared with budesonide alone (16.5 L/min vs 7.3 L/min, p = 0.002). Similarly, evening PEF was significantly greater in the budesonide/formoterol group (p &lt; 0.001). In addition, the percentage of symptom-free days and asthma-control days (p = 0.007 and p = 0.002, respectively) were significantly improved in the budesonide/formoterol group. Budesonide/formoterol decreased the relative risk of an asthma exacerbation by 26% (p = 0.02) compared with budesonide alone. Adverse events were comparable between the two treatment groups. Conclusion: This study shows that in adult patients whose mild-to-moderate asthma is not fully controlled on low doses of inhaled corticosteroids, single-inhaler therapy with budesonide and formoterol provides greater improvements in asthma control than increasing the maintenance dose of inhaled corticosteroid.},
  author       = {Lalloo, UG and Malolepszy, J and Kozma, D and Krofta, K and Ankerst, Jaro and Johansen, B and Thomson, NC},
  issn         = {1931-3543},
  keyword      = {formoterol,inhaled corticosteroids,long-acting,beta(2)-agonists,Symbicort,asthma,budesonide},
  language     = {eng},
  number       = {5},
  pages        = {1480--1487},
  publisher    = {American College of Chest Physicians},
  series       = {Chest},
  title        = {Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma},
  volume       = {123},
  year         = {2003},
}